Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia

American Journal of Clinical Pathology

Volumn 106, Issue 4, 1996, Pages 457-461

  Tefferi, Ayalew ^a   Bartholmai, Brian J ^b   Witzig, Thomas E ^a   Li, Chin Yang ^a   Hanson, Curtis A ^a   Phyliky R, Robert L ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic ^*

Author keywords

Fluorescence; Leukemia; Lymphocytes; Phenotyping; Prognosis

Indexed keywords

CD20 ANTIGEN; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0029763585     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/106.4.457     Document Type: Article

References (13)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J Clin Pathol 1989;42:567-584.
2. Tefferi A, Li C-Y, Phyliky RL. Role of immunotyping in chronic lymphocytosis: Review of the natural history of the condition in 145 adult patients. Mayo Clin Proc 1988;63:801-806.
3. Newman RA, Peterson B, Davey FR, et al. Phenotypic markers and bcl-1 gene rearrangements in B-cell chronic lymphocytic leukemia: A Cancer and Leukemia Group B study. Blood 1993;82:1239-1246.
4. Witzig TE, Li C-Y, Tefferi A, Katzmann JA. Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 1994;101:312-317.
5. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992;40:259-263.
6. Marti GE, Faguet G, Bertin P, et al. CD20 and CD5 expression in B-chronic lymphocytic leukemia. Ann N Y Acad Sci 1992;651: 480-483.
7. Bassan R, Pronesti M, Buzzetti M, et al. Surface immunoglobulin intensivity and p67 (CD5) antigen expression define different forms of B-cell chronic lymphocytic leukaemia. Haematologica 1987;72:221-225.
8. Tefferi A, Li C-Y, Phyliky RL. Correlation of clinical outcome with the degree of surface immunoglobulin (sIg) expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 1989;92:82-85.
9. Freedman AS, Boyd AW, Bieber FR, et al. Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood 1987;70: 418-427.
10. Terstappen LW, de Grooth BG, van Berkel W, ten Napel CH, Greve J. Flow cytometric characterization of chronic lymphocyte leukaemias using orthogonal light scattering and quantitative immunofluorescence. Blut 1988;56:201-208.
11. Lavabre-Bertrand T, Exbrayat C, Bourquard P, et al. CD23 antigen density is related to serum gamma globulin level, bone marrow reticulin pattern, and treatment in B chronic lymphocytic leukemia. Leuk Lymphoma 1994;13:89-94.
12. Geisler CH, Larsen JK, Hansen NE, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 1991;78:1795-1802.
13. Maddy AH, Sanderson A, Mackie MJ, Smith SK. The role of cell maturation in the generation of phenotypic heterogeneity in B-cell chronic lymphocytic leukaemia. Immunology 1989;68: 346-352.